

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PuraPharm

PURAPHARM CORPORATION LIMITED

培力控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1498)

PROPOSED CHANGE OF COMPANY NAME

PROPOSED CHANGE OF COMPANY NAME

The Board announces that the Company proposes to change its dual foreign name in Chinese from “培力控股有限公司” to “培力農本方有限公司”. The Change of Company Name is subject to the approval by the Shareholders at the AGM by way of a special resolution and the approval of the Registrar of Companies in the Cayman Islands.

GENERAL

At the AGM, a special resolution will be proposed for the Shareholders to consider and, if thought fit, approve the proposed Change of Company Name. A circular containing, amongst other things, details regarding the proposed Change of Company Name, together with the notice of AGM and the related proxy form will be despatched to the Shareholders as soon as practicable.

PROPOSED CHANGE OF COMPANY NAME

The board of directors (“**Board**”) of PuraPharm Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the Company proposes to change its dual foreign name in Chinese from “培力控股有限公司” to “培力農本方有限公司” (the “**Change of Company Name**”). A special resolution will be proposed at the upcoming annual general meeting of the Company (the “**AGM**”) to consider and, if thought fit, approve the proposed Change of Company Name, among others.

CONDITIONS OF THE PROPOSED CHANGE OF COMPANY NAME

The proposed Change of Company Name will be subject to the following conditions:

1. the passing of a special resolution by the shareholders of the Company (the “**Shareholders**”) at the AGM approving the Change of Company Name; and
2. the approval being granted by the Registrar of Companies in Cayman Islands for the Change of Company Name.

Subject to the satisfaction of the conditions set out above, the proposed Change of Company Name will take effect from the date upon the issue of a certificate of incorporation on adoption of dual foreign name by the Registrar of Companies in the Cayman Islands confirming that the new dual foreign name has been registered. Upon receiving the requisite approval from the Registrar of Companies in the Cayman Islands, the Company will carry out all necessary filings with the Companies Registry in Hong Kong thereafter.

REASONS FOR THE PROPOSED CHANGE OF COMPANY NAME

The Group is a leading Hong Kong-based Chinese medicine company primarily engaged in the research and development, production, marketing and sale of concentrated Chinese medicine granules (“**CCMG**”) products. The Board considers that the Change of Company Name will promote its brand Nong’s® (農本方®) and enhance the corporate identity of the Group in engaging development, production, marketing and sale of CCMG products. The Board believes that the new Chinese names of the Company will provide the Company with a new corporate image which will benefit the Company’s future business development. As such, the Board believes that the change is in the best interests of the Company and the Shareholders as a whole.

EFFECTS OF THE CHANGE OF COMPANY NAME

The proposed Change of Company Name will not affect any rights of the existing holders of the shares of the Company (the “**Shares**”) nor the Company’s daily business operation and its financial position. All the existing share certificates of the Company in issue bearing the existing name of the Company will, upon the proposed Change of Company Name becoming effective, continue to be evidence of title to such Shares and will continue to be valid for trading, settlement, registration and delivery of such Shares. There will not be any arrangement for free exchange of the existing share certificates of the Company for new share certificates printed in the new names of the Company. Upon the Proposed Change of Company Name becoming effective, all new share certificates will only be issued in the new Chinese name of the Company.

In addition, subject to the confirmation by The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), the Chinese stock short name for trading of the Shares in the Stock Exchange will also be changed after the proposed Change of Company Name has become effective.

GENERAL

At the AGM, a special resolution will be proposed for the Shareholders to consider and, if thought fit, approve the proposed Change of Company Name. A circular containing, amongst other things, details regarding the proposed Change of Company Name, together with the notice of AGM and the related proxy form will be despatched to the Shareholders as soon as practicable.

The Company will make further announcement(s) to inform the Shareholders of the poll results of the special resolution, the effective date of the Proposed Change of Company Name and the new Chinese stock short name of the Company under which the Shares will be traded on the Stock Exchange as and when appropriate.

By Order of the Board
PuraPharm Corporation Limited
Chan Yu Ling, Abraham
Chairman

Hong Kong, 21 April 2021

As at the date of this announcement, the executive directors of the Company are Mr. Chan Yu Ling, Abraham, Dr. Tsoi Kam Biu, Alvin, Ms. Man Yee Wai, Viola, Mr. Cheong Shin Keong and Dr. Norimoto Hisayoshi; the non-executive directors of the Company are Mr. Chow, Stanley and Mr. Chan Kin Man, Eddie; and the independent non-executive directors of the Company are Dr. Chan Kin Keung, Eugene, Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.